Genialis and Inventia Life Sciences agreed to work together to improve how new treatments for pancreatic cancer are tested and matched to the patients most likely to benefit. The companies will combine Genialis’ AI-powered patient insights with Inventia’s RASTRUM 3D cell model platform to build human-relevant models of pancreatic ductal adenocarcinoma (PDAC) that correspond to the tumor biology of identifiable patient populations.
Initial results from this collaboration will be presented this week at the Pancreatic Cancer Action Network (PanCAN)’s 2026 Scientific Summit in San Diego.
Recent advances in targeted therapies for pancreatic cancer have brought renewed attention to PDAC and underscored the need for better strategies to identify which patients are most likely to benefit from new treatments. Inventia’s RASTRUM platform prints reproducible 3D pancreatic cancer models in which tumor and stromal components can be controlled and perturbed independently.
Genialis characterizes those models with…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
